OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS | Real-time Bid/Ask 11:24:05 06/06/2024 pm IST | ||
| 2.49 EUR / 2.79 EUR | -6.38% |
|
| Current month | +59.32% | ||
| 1 month | +984.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 06/24/06 | 2.67 | -5.32% |
| 05/24/05 | 2.82 | +8.46% |
| 04/24/04 | 2.6 | +16.07% |
| 03/24/03 | 2.24 | +26.55% |
| 31/24/31 | 1.77 | -26.56% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 11:42 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX34NS |
| ISIN | DE000LX34NS8 |
| Date issued | 24/04/2024 |
| Strike | 0.4543 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 0.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.28 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.3 € |
| Spread % | 10.75% |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.65
EUR
Average target price
41.57
EUR
Spread / Average Target
+1,468.55%
- Stock Market
- Certificates
- Certificat
